en · de · es · pt
melanotan-2-notes.peptides3626.com › Topic › Background And Chemical Profile — Worked Examples

Background And Chemical Profile — Worked Examples

By Editorial Desk · published 2025-07-08 · last reviewed 2025-07-28 · Topic

cyclic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Regulation, Literature and Verification

Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Melanotan-2 Structure and Receptor Pharmacology

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

Related pages on this site

Handling, Storage and Analytical Control

Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.

Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Quality Control and Analytical Practice

Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.

Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.

Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.

Supporting material

== Carbamino compounds in blood == The concentration of carbamate (HbCO2) was estimated in oxygenated and deoxygenated red blood cells of adult and fetal humans. The estimation was carried out at a constant pressure of carbon dioxide (PCO2 = 40 mm Hg) and varied pH levels of the serum. The bicarbonate concentration in the red cells was calculated using the Donnan ratio for chloride and bicarbonate ions. Based on this figure, the carbamate concentration was determined by subtracting the bicarbonate concentration and dissolved CO2 from the total CO2 concentration. Deoxygenated fetal red cells contain more HbCO2 than deoxygenated adult red cells at a given pH value in the red cell. Upon oxygenation, HbCO2 decreased in both types of erythrocytes to values lower than in deoxygenated cells, at a constant pH. The fraction of 'oxylabile carbamate' (-ΔHbCO2/ΔHbO2) at a red cell pH of 7·2 and a PCO2 of 40 mm Hg is 0·117 in fetal and 0·081 in adult erythrocytes. The apparent carbamate equilibrium constants (K'c and K'z) were calculated from the fraction of moles carbamate formed per Hb monomer (moles CO2/mole Hbi). These constants can be used to estimate the carbamate concentration in normal adult and fetal blood. In adult red cells, the first apparent dissociation constant of carbonic acid is significantly higher in oxygenated (-log10K'1 = pK'1 = 6·10) than in deoxygenated (pK'1 = 6·12) red cells, whereas in fetal red cells, the difference is smaller and statistically not significant.

The ICD-11 instead distinguishes a harmful episode of use, a harmful pattern of use, and dependence. Prevention approaches with the strongest supporting evidence include family skills programs, school-based personal and social skills education, and policies that limit availability and raise price. Addiction is managed as a chronic, relapsing condition, usually combining medication, where an effective one exists, with psychological and social support. Effective medications are available for opioid, alcohol, and tobacco use disorders, but none is approved for stimulant use disorder, for which psychosocial treatment remains the mainstay. Harm reduction measures address the damage associated with continued use. Outcomes vary widely: an estimated 35–54% of people with a substance use disorder reach remission, though typically only after many years. About 163 million people worldwide were estimated to be living with a substance use disorder in 2021, most commonly alcohol use disorder, and drug use was one of only three risk factors whose age-standardized attributable burden rose between 2010 and 2023. Addiction carries substantial economic and social costs, and anthropological and structural accounts situate heavy drug use within cultural norms and unequal distributions of power.

Nevertheless, among different absorption-based techniques which are used for gaseous species detection, Cavity ring-down spectroscopy (CRDS) can be used as a calibration-free method. The fact that CRDS is based on the measurements of photon life-times (and not the laser intensity) makes it needless for any calibration and comparison with a reference Some instruments also automatically identify the substance being measured from a store of thousands of reference spectra held in storage.

==== Mixed apnea ==== Some people with sleep apnea have a combination of both types; its prevalence ranges from 0.56% to 18%. The condition, also called treatment-emergent central apnea, is generally detected when obstructive sleep apnea is treated with CPAP and central sleep apnea emerges. The exact mechanism of the loss of central respiratory drive during sleep in OSA is unknown but is most likely related to incorrect settings of the CPAP treatment and other medical conditions the person has.

Sources: en.wikipedia.org

Notes from published material

there were many isolated subdisciplines within neuroscience with little contact between them many people who were interested in behaviour treated the brain as a black box consciousness was viewed as a taboo subject by many neurobiologists Crick hoped he might aid progress in neuroscience by promoting constructive interactions between specialists from the many different subdisciplines concerned with consciousness. He also collaborated with neurophilosophers such as Patricia Churchland. In 1983, as a result of their studies of computer models of neural networks, Crick and Mitchison proposed that the function of REM sleep and dreaming is to remove certain modes of interactions in networks of cells in the mammalian cerebral cortex; they called this hypothetical process "reverse learning" or "unlearning". In the final phase of his career, Crick established a collaboration with Christof Koch that led to publication of a series of articles on consciousness during the period spanning from 1990 to 2005. Crick made the strategic decision to focus his theoretical investigation of consciousness on how the brain generates visual awareness within a few hundred milliseconds of viewing a scene. Crick and Koch proposed that consciousness seems so mysterious because it involves very short-term memory processes that are as yet poorly understood. In his book The Astonishing Hypothesis, Crick described how neurobiology had reached a mature enough stage so that consciousness could be the subject of a unified effort to study it at the molecular, cellular and behavioural levels.

==== Effects on liver protein synthesis ==== A study compared the combination of 5 mg estradiol cypionate and 25 mg medroxyprogesterone acetate as a combined injectable contraceptive (which has been associated with peak estradiol levels of around 300 pg/mL) with an ethinylestradiol-containing combined birth control pill and found that whereas the birth control pill produced significant changes in coagulation parameters, there were no significant prothrombotic effects of the combined injectable contraceptive on levels of fibrinogen, factors VII and X, plasminogen, or the activated prothrombin time. As such, it appears that similarly to depot medroxyprogesterone acetate, combined injectable contraceptives with 5 mg estradiol cypionate and 25 mg medroxyprogesterone acetate have less or no procoagulant effect relative to combined birth control pills.

== In education == The Portal games have found application in educational aspects outside of game development. The first game was praised as an example of instructional scaffolding where the student is first given an environment to learn new tools with sufficient hand-holding, but these facets are slowly removed as the student proceeds. At least one college, Wabash College, introduced Portal as part of required coursework; at Wabash; the game is used as an example of Erving Goffman's dissemination on dramaturgy, The Presentation of Self in Everyday Life. At a mid-2011 presentation at the 2011 Games for Change Festival at New York University, Gabe Newell stated Valve's intention to direct Portal and Portal 2 towards education. Newell stated that Valve "doesn't see divide between making a game that can do well and be educational", and was already working with schools to develop lesson plans around the game. In one example, Valve brought in students from nearby Evergreen School to watch them interact with the game in an educational setting. As part of this effect, the company promoted Portal for free use by any user during September 2011. In speaking at the 2012 Games for Change Festival, Newell said that the response to these efforts was praised by educators. Their efforts culminated in a "Teach with Portals" program that Newell announced at the Festival. The effort is built on a standalone "Puzzle Maker" that incorporates the level editor for Portal 2 that was released as free content for the game in early 2012.

=== Role in Infectious Disease Pathogenesis === Certain pathogens, such as Enterotoxigenic Escherichia coli (ETEC), elevate cGMP to evade host immune defenses and establish infection. ETEC's heat-stable toxin induces significant cGMP production within intestinal epithelial cells, and this cGMP is often secreted into the extracellular space, where it serves as a signaling molecule. Extracellular cGMP, in turn, triggers the release of IL-33 release which modulate inflammation and impact the immune system's ability to mount effective responses, dampening both innate and adaptive immunity.

The Peaceful Revolution of 1989 resulted in the Socialist Unity Party of Germany giving up its monopoly on power, and permitting opposition parties to operate for the first time. They began to form in large numbers throughout November and December 1989. Opposition groups formed the East German Round Table, which was joined by representatives of the SED to negotiate reforms; at its first meeting on 7 December 1989, the Round Table agreed that elections to the Volkskammer would be held on 6 May 1990.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network